Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Accelerated Radiation + Capecitabine in Pancreatic Cancer
NCT00889187Phase 2Terminated
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Dec 2009
- Primary completion
- Dec 2011
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of capecitabine in pancreatic ductal adenocarcinoma (PDAC), sponsored by Dana-Farber Cancer Institute. Started Dec 2009; status: terminated.
02
Drugs
capecitabine
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT00889187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00889187.